Beta blockers inhibit the chronotropic, inotropic, and vasoconstrictor responses to the catecholamines, epinephrine and norepinephrine by blocking beta receptors in the heart and vasculature. Beta blockers are used for various indications specific to each beta blocker and can include hypertension, chronic stable angina, atrial arrhythmias, asymptomatic and symptomatic heart failure, migraine, and secondary prevention post-myocardial infarction. The purpose of this review is to compare the efficacy, effectiveness, and harms of beta blockers.
Copyright & 2007, Oregon Health & Science University, Portland, Oregon.
Helfand M, Peterson K, Christensen V, Dana T, Thakurta S. Helfand M, et al. Portland (OR): Oregon Health & Science University; 2009 Jul. Portland (OR): Oregon Health & Science University; 2009 Jul. PMID: 21089245 Free Books & Documents. Review.
Freitas M. Freitas M. Rev Port Cardiol. 1993 Nov;12 Suppl 4:19-28, 7-8. Rev Port Cardiol. 1993. PMID: 7904458 Review. Portuguese.
Bangalore S, Parkar S, Messerli FH. Bangalore S, et al. Anadolu Kardiyol Derg. 2006 Dec;6(4):358-63. Anadolu Kardiyol Derg. 2006. PMID: 17162285 Review.
Leenen FH, Davies RA, Fourney A. Leenen FH, et al. Clin Pharmacol Ther. 1998 Nov;64(5):522-35. doi: 10.1016/S0009-9236(98)90135-7. Clin Pharmacol Ther. 1998. PMID: 9834044 Clinical Trial.
Genovesi Ebert A, Colivicchi F, Malvezzi Caracciolo M, Riccio C. Genovesi Ebert A, et al. Monaldi Arch Chest Dis. 2009 Mar;72(1):18-22. doi: 10.4081/monaldi.2009.338. Monaldi Arch Chest Dis. 2009. PMID: 19645208 Review.
The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.